Immunology Blog
The articles listed here are updated regularly and address cutting-edge research addressing the unique immunology found in the liver.Â
Mastering Multidirectional Tactics in HCC: Expert Guidance on Emerging Trends With Systemic Therapy Options Across the Disease Continuum
The team at MD Anderson Proton Therapy Center continues to expand ways to use proton therapy to benefit patients. The team pioneered pencil beam proton therapy, also called scanning beam, and intensity modulated proton therapy (IMPT). We are one of the few centers...
Immunotherapy in HCC: Improving Outcomes Across the Disease Continuum
Watch this video on treating patients with hepatocellular carcinoma following guideline recommendations and current data in immunotherapy to improve outcomes. Learn More
AKR1B10 expression characteristics in hepatocellular carcinoma and its correlation with clinicopathological features and immune microenvironment
This study aims to explore the expression characteristics of AKR1B10 in HCC and its correlation with clinicopathological features, survival prognosis, and tumor immune microenvironment, further investigating its role and potential regulatory mechanisms in HCC. Learn...
Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer
Fibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The disease is caused by a single genetic mutation that creates a fusion protein. Scientists at St. Jude Children's Research Hospital and The University of...
Immune evasion tactics of liver cancer cells revealed
A faulty cancer gene helps tumors evade immunity by stopping tumor cells releasing message-containing cargoes called exosomes. These findings, published in eLife, provide what the editors say is fundamental insight into the underlying biology of hepatocellular...
Finding the Right Targets to Treat Biliary Tract Cancers
The most recent FDA approval related to BTC came in October 2023 with an expanded indication for pembrolizumab to be used in combination with gemcitabine (Gemzar) and cisplatin for the treatment of locally advanced unresectable or metastatic BTC. This was based on the...
Liver Cancer: A Promising Avenue for More Effective Immunotherapies
Hepatocellular carcinoma is associated with known risk factors such as chronic hepatitis B or C infection, alcohol abuse, and metabolic dysfunction. It is the most common type of liver cancer. Despite major advances in immunotherapy, this cancer is often fatal: around...
Tumor Immune Microenvironment and the Current Immunotherapy of Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a highly heterogeneous malignancy originating from the epithelial system of the bile ducts, and its incidence in recent years is steadily increasing. The immune microenvironment of CCA is characterized by diversity and complexity, with a...
A next-generation treatment for bile duct cancer
Tinengotinib has a unique binding mechanism away from the ATP binding pocket that enables it to target even newly resistant cancer cells. It overcomes acquired resistance by targeting FGFR2 kinase domain mutations. Essentially, by inhibiting a number of different...
The Immunological and Metabolic Landscape in Primary and Metastatic Liver Cancer
The liver is the sixth most common site of primary cancer in humans, and generally arises in a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by metastases from cancers of other organs (particularly the colon) because of its...